

4 INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of	1
-------	---	----	---

Application Number	09/910,345
Filing Date	July 20, 2001
First Named Inventor	H. Michael Shepard, et al
Art Unit	1045-1631
Examiner Name	<i>Smith</i> Not Yet Assigned
Attorney Docket Number	NB 2017.00

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code ² (if known)			
CS	1	US-6,245,750	06/12/01	Shepard et al.	
		US-			
		US-			
		US-			
		US-			
		US-			

[illegible]

Date Considered 12/2/03

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

52076239.1/23896-7101

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	09/910,345
Filing Date	July 20, 2001
First Named Inventor	H. Michael Shepard, et al.
Art Unit	1631-1645
Examiner Name	Smith Not Yet Assigned
Attorney Docket Number	NB 2017.00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published
CS	1	AMYES, S.G. et al. (1992) "Classification of plasmid-encoded dihydrofolate reductases conferring trimethoprim resistance." <i>J. Med. Microbiol.</i> 36:1-3.
	2	ARTHUR, Michel, et al. (August 1999) "Moderate-Level Resistance to Glycopeptide LY333328 Mediated by Genes of the <i>vanA</i> and <i>vanB</i> Clusters in Enterococci" <i>Antimicrobial Agents and Chemotherapy</i> 43(8):1875-1880.
	3	AULABAUGH, Ann, et al. (1990) "Oxalyl Hydroxamates as Reaction-Intermediate Analogues for Ketol-Acid Reductoisomerase." <i>Biochemistry</i> 29(11):2824-2830.
	4	BERGER-BÄCHI, Brigitte, et al. (1989) "FemA, a host-mediated factor essential for methicillin resistance in <i>Staphylococcus aureus</i> : Molecular cloning and characterization" <i>Mol. Gen. Genet.</i> 219:263-269.
	5	BLIGHT, Keril J., et al. (1998) "Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets" <i>Antivir. Ther.</i> 3(Suppl 3):71-81.
	6	BLOOMER, James L., et al. (1976) "Microbial Metabolites. Part XI. Total Synthesis and Absolute Configuration of (S)-Carlosic Acid (4-Butyryl-2,5-dihydro-3-hydroxy-5-oxo-furan-2-acetic Acid) and Conversion of (R)-5-Methyltetronic Acid into (R)-Carolic Acid {3,4-Dihydro-8-methylfuro[3,4-b]oxepin-5,6(2H,8H)-di-one}" <i>J. Chem. Soc., Perkin Trans. I</i> 14:1485-1491.
	7	BOHACEK, Regine S, et al. (1997) "Modern computational chemistry and drug discovery: structure generating programs" <i>Curr. Opin. Chem. Biol.</i> 1:157-61.
	8	BONOMO, Robert A., et al. (May 15, 1999) "Inhibitor Resistant Class A Beta-Lactamases" <i>Front Biosci.</i> 4:34-41.
	9	CACERES, Nancy E., et al. (August 1997) "Overexpression of the D-Alanine Racemase Gene Confers Resistance to D-Cycloserine in <i>Mycobacterium smegmatis</i> ." <i>J. Bacteriol.</i> 179(16):5046-5055.
	10	CARLSEN, Per H.J., et al. (1981) "A Greatly Improved Procedure for Ruthenium Tetraoxide Catalyzed Oxidations of Organic Compounds." <i>J. Org. Chem.</i> 46:3936-3938.
	11	CASADEWALL, Barbara, et al. (June 1999) "Characterization of the <i>vanD</i> Glycopeptide Resistance Gene Cluster from <i>Enterococcus faecium</i> BM4339." <i>J. Bacteriol.</i> 181(12):3644-3648.
	12	CASADO, Jose L., et al. (2000) "Non-nucleoside reverse transcriptase inhibitor resistance among patients falling a nevirapine plus protease inhibitor-containing regimen" <i>AIDS</i> 14(2):F1-F7.
	13	CHANG, Alan K., et al. (1998) "Herbicide-resistant forms of <i>Arabidopsis thaliana</i> acetohydroxyacid synthase: characterization of the catalytic properties and sensitivity to inhibitors of four defined mutants" <i>Biochem. J.</i> 333: 765-777.
	14	CHIPMAN, David, et al. (1998) "Biosynthesis of 2-aceto-2-hydroxy acids: acetolactate synthases and acetohydroxyacid synthases" <i>Biochim. Biophys. Acta</i> 1385:401-419.
	15	COHEN, Noal, et al. (1983) "Enantiospecific Syntheses of Leukotrienes C ₄ D ₄ and E ₄ and [14, 15- ³ H ₂] Leukotriene E ₄ Dimethyl Ester." <i>J. Am. Chem. Soc.</i> 105:3661-3672.
	16	DEGRAW, Joseph I., et al. (January-February 1986) "Synthesis of 5,10-Dideazaminopterin." <i>J. Heterocyclic Chem.</i> 23:1-4.
	17	DÖTZ, K.H. (1999) "Reactions of complex ligands 85: chiral quinoid and hydroquinoid [2.2]metacyclophanes via chromium-mediated intramolecular benzannulation." <i>J. Organomet. Chem.</i> 578:223-228.
	18	EKINS, Sean, et al. (1999) "Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors." <i>Pharmacogenetics</i> 9:477-489.
	19	EKINS, Sean, et al. (1999) "Three-Dimensional-Quantitative Structure Activity Relationship Analysis of Cytochrome P-450 3A4 Substrates." <i>J. Pharmacol. Exp. Ther.</i> 291(1):424-433.
	20	EVANS, M. E., et al. (1967) "Acetal Exchange Reaction" <i>Carbohydrate Res.</i> 3:453-462.

RECEIVED

TECH CENTER 1800/2900
APR 2 2002

Sheet	2	of	3	Attorney Docket Number	NB 2017.00
-------	---	----	---	------------------------	------------

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published
APR 19 2002 PATENT & TRADEMARK OFFICE		FREER, Andrew A., et al. (1996) "Synthesis and absolute configurations of the naturally occurring 3- and 4-methylmuconolactones: X-ray structures of (S)-1-phenylethylammonium salts and an 8-bromo-1-methyl-muconodilactone" <i>J. Chem. Soc. Perkin Trans. 1</i> 17:2111-2116.
		GYPSEER, Andreas, et al. (1997) "D-Erythronolactone as a C ₄ building unit. Part 2. A short and efficient synthesis of both enantiomers of elp-muricatacin, a diastereoisomer of the native acetogenin from <i>Annona muricata</i> ." <i>Chem. Soc. Perkin Trans. 1</i> , p.1013-1016
	23	GYPSEER, Andreas, et al. (1994) "D-Erythronolactone and 2,3-O-Isopropylidene-L-erythrose as C ₄ Building Units: An Efficient Synthesis of both Enantiomers of <i>endo</i> -Brevicomine and its 7-Vinyl Analogues" <i>Liebigs. Ann. Chem.</i> , 775-780.
	24	HALGAND, Frédéric, et al. (1999) "Characterization of the Conformational Changes of Acetohydroxy Acid Isomeroreductase Induced by the Binding of Mg ²⁺ Ions, NADPH, and a Competitive Inhibitor [†] " <i>Biochemistry</i> 38:6025-6034.
	25	HANAKI, H., et al. (1998) "Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant <i>Staphylococcus aureus</i> clinical strains Mu3 and Mu50" <i>J. Antimicrob. Chemother.</i> 42(2):199-209.
	26	HANESSIAN, Stephen, et al. (1983) "Total synthesis of the C-3 – C-17 segment of boromycin" <i>Can. J. Chem.</i> 61:634-637.
	27	HARMS, Christian T., et al. (1992) "Herbicide resistance due to amplification of a mutant acetohydroxyacid synthase gene." <i>Mol. Gen. Genet.</i> 233:427-435.
	28	HILL, Craig M., et al. (1997) "Purification of <i>Escherichia coli</i> acetohydroxyacid synthase isoenzyme II and reconstitution of active enzyme from its individual pure subunits" <i>Biochem. J.</i> 327:891-898.
	29	IBDAH, Muhammad, et al. (1996) "Homology Modeling of the Structure of Bacterial Acetohydroxy Acid Synthase and Examination of the Active Site by Site-Directed Mutagenesis" <i>Biochemistry</i> 35:16282-16291.
	30	KIRKPATRICK, Lynn D., et al. (1999) "Structure-Based Drug Design: Combinatorial Chemistry and Molecular Modeling" <i>Comb. Chem. High Throughput Screen</i> 2:211-221.
	31	KLEANTHOUS, Collin, et al. (1985) "3-(Bromoacetyl)chloramphenicol, an Active Site Directed Inhibitor for Chloramphenicol Acetyltransferase" <i>Biochemistry</i> 24:5307-5313.
	32	LACKEY, David B., et al. (2001) "Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase" <i>Biochem. Pharmacol.</i> 61:179-189.
	33	LESSARD, Ivan A. D., et al. (1999) "Determinants for Differential Effects on D-Ala-D-Lactate vs D-Ala-D-Ala Formation by the VanA Ligase from Vancomycin-Resistant Enterococci" <i>Biochemistry</i> 38:14006-14022.
	34	LEWBART, Marvin L., et al. (November 1969) "Preparation and Properties of Steroidal 17,20- and 20,21-Acetonides Epimeric at C-20. I. Derivatives of 5 β -Pregnan-3 α -ol" 34(11):3505-3512.
	35	LIPSHUTZ, Bruce H., et al. (1988) "Acyclic Control of Stereochemistry via a Reiterative (E or Z)-1-Propenyllithium-Derived Cuprate Opening of a Chiral Epoxide/Reepoxidation Sequence" <i>J. Org. Chem.</i> 53:4495-4499.
	36	MALIK, Arshad, et al. (May 2, 2000) "Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium" <i>Ann. Intern. Med.</i> 132(9):723-731.
	37	MCGOWAN, Donald A., et al. (1982) "Total Synthesis of Racemic Chorismic Acid" <i>J. Am. Chem. Soc.</i> 104:1153-1154.
	38	MCGOWAN, Donald A., et al. (1982) "Total Synthesis of Racemic Chorismic Acid and (-)-5-Enolpyruvylshikimic Acid ("Compound Z ₁ ")" <i>J. Am. Chem. Soc.</i> 104:7036-7041.
	39	MCKAGUE, A. Bruce (1999) "Synthesis of Muconic Acids By Peracetic Acid Oxidation of Catechols." <i>Synth. Commun.</i> 29(9):1463-1475.
	40	MDLULI, Khisimuzi, et al. (1998) "Mechanisms involved in the intrinsic isoniazid resistance of <i>Mycobacterium avium</i> ." <i>Molecular Microbiology</i> 27(6):1223-1233.
	41	MIESSEL, Lynn, et al. (1998) "Mechanisms for Isoniazid action and resistance" <i>Novartis Found. Symp.</i> 217:209-220.
	42	PANG, Siew Siew, et al. (1999) "Expression, Purification, Characterization, and Reconstitution of the Large and Small Subunits of Yeast Acetohydroxyacid Synthase" <i>Biochemistry</i> 38:5222-5231.
	43	PATRICK, Timothy B., et al. (1994) "New Fluorobutenolide Templates for Synthesis" <i>J. Org. Chem.</i> 59:1210-1212.
	44	PIRRUNG, Michael C., et al. (1991) "Mechanism and Stereochemistry of α,β -Dihydroxyacid Dehydratase" <i>J. Am. Chem. Soc.</i> 113:1020-1025.
	45	POULSEN, Charlotte, et al. (1989) "Purification and properties of <i>Saccharomyces cerevisiae</i> acetolactate synthase from recombinant <i>Escherichia coli</i> " <i>Eur. J. Biochem.</i> 185:433-439.

RECEIVED

APR 22 2002

TECH CENTER 1501/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published
	46	RAYNAUD, Catherine, et al. (1999) "Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity" <i>Microbiology</i> 145:1359-1367.
		READ, Timothy D., et al. (September 2001) "Finding drug targets in microbial genomes." <i>DDT</i> 6(17):887-892.
		SHAW, Karen J. et al. (March 1980) "Salmonella typhimurium Mutants Defective in Acetohydroxy Acid Synthases I and II" <i>J. Bacteriol.</i> 141(3):1258-1263.
	49	SHAW, William V., et al. (1988) "Tinkering with antibiotic resistance: chloramphenicol acetyltransferase and its substrates" <i>Biochem. Soc. Trans.</i> 16:939-942.
	50	SHAW, W., et al. (1991) "Chloramphenicol Acetyltransferase" <i>Annu. Rev. Biophys. Biophys. Chem.</i> 20:363-86.
	51	STASCHKE, Kirk A., et al. (1995) "Molecular Basis for the Resistance of Influenza Viruses to 4-Guanidino-Neu5Ac2en." <i>Virology</i> 214:642-646.
	52	SVENDSEN, Axel, et al. (1975) "Naturally Occurring Lactones and Lactams. VIII. Lactonization of Unsaturated β -Keto Esters. Total Synthesis of Caric Acid, Carosic Acid, and Viridic Acid" <i>J. Org. Chem.</i> 40(13):1927-1932.
	53	TAKABATAKE, Tohru, et al. (1992) "Bacteriostatic Effect of 4,7-Dicyanobenzofurazan Due to Inactivation of 2,3-Dihydroxyisovalerate Dehydratase" <i>Chem. Pharm. Bull.</i> 40(6):1644-1646.
	54	TETTELIN, Hervé et al. (July 20, 2001) "Complete Genome Sequence of a Virulent Isolate of <i>Streptococcus pneumoniae</i> " <i>Science</i> 293:498-506.
	55	VAGHEFI, Morteza M., et al. (1986) "Synthesis and Antiviral Activity of Certain Nucleoside 5'-Phosphonoformate Derivatives" <i>J. Med. Chem.</i> 29:1389-1393.
	56	VANRHEENEN, V., et al. (1976) "An Improved Catalytic OsO ₄ Oxidation of Olefins to <i>CIS</i> -1, 2-Glycols Using Tertiary Amine Oxides as the Oxidant" <i>Tetrahedron Letters</i> 23:1973-1976.
	57	VARGHESE, Joseph N, et al. (1998) "Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase" <i>Structure</i> 6(6):735-746.
	58	VENTURI, Guilietta, et al. (2000) "Antiretroviral Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Protease from Paired Cerebrospinal Fluid and Plasma Samples" <i>J. Infect. Dis.</i> 181:740-745.
	59	VOLLMER, Martin Dominik, et al. (July 1994) "Inability of Muconate Cycloisomerases to Cause Dehalogenation during Conversion of 2-Chloro- <i>cis,cis</i> -Muconate" <i>J. Bacteriol.</i> 176(14):4366-4375.
	60	VOLLMER, Martin Dominik, et al. (May 1995) "Conversion of 2-Chloro- <i>cis,cis</i> -Muconate and Its Metabolites 2-Chloro- and 5-Chloromuconolactone by Chloromuconate Cycloisomerases of pJP4 and pAC27" <i>J. Bacteriol.</i> 177(10):2938-2941.
	61	VOLLMER, Martin Dominik, et al. (September 1998) "Substrate Specificity of and Product Formation by Muconate Cycloisomerases: an Analysis of Wild-Type Enzymes and Engineered Variants." <i>Appl. Environ. Microbiol.</i> 64(9):3290-3299.
	62	WEINSTOCK, Oma, et al. (September 1992) "Properties of Subcloned Subunits of Bacterial Acetohydroxy Acid Synthases" <i>J. Bacteriol.</i> 174(17):5560-5566.
	63	WHITCOMB, Carl E. (1999) "An introduction to ALS-inhibiting herbicides" <i>Toxicol. Ind. Health</i> 15:231-239.
	64	YUAN, Ying, et al. (July 1995) "Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in <i>Mycobacterium tuberculosis</i> " <i>Proc. Natl. Acad. Sci. USA.</i> 92:6630-6634.
	65	ZHDANOV, Yu. A., et al. (August 1971) "Reformatsky Reaction in the Carbohydrate Series" <i>Zh. Obshch. Khim</i> 41(8):1845-1847.

Examiner's Signature		Date Considered	12/2/03
----------------------	---	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

APR 30 2002

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 14498-PTO

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	09/910,345
Filing Date	July 20, 2001
First Named Inventor	H. Michael Shepard, et al.
Art Unit	1631 1645
Examiner Name	Smith Not Yet Assigned
Attorney Docket Number	NB 2017.00

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

[illegible]

RECEIVED

~~MAY 03 2002~~

TECH CENTER 1600/2900

**Examiner's
Signature**

Date
Considered

12/2/53

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.**

AUG 05 2002

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/910,345
Filing Date	July 20, 2001
First Named Inventor	H. Michael SHEPARD
Art Unit	1631 -1645-
Examiner Name	Smith Not Yet Assigned
Attorney Docket Number	NB 2017.00

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

RECEIVED

AUG 08 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
CS	1	WO 99/08110	02-18-99	NewBiotics, Inc.		
	2	WO 99/37753	07-28-99	NewBiotics, Inc.		
	3	WO 01/07087	02-01-00	NewBiotics, Inc.		
	4	WO 01/07088	02-01-01	NewBiotics, Inc.		
	5	WO 01/64687	09-07-01	NewBiotics, Inc.		
	6	WO 01/83492	11-08-01	NewBiotics, Inc.		

Examiner's
SignatureDate
Considered

12/2/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the P

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

(use as many sheets as necessary)

Complete if Known

Application Number	09/910,345
Filing Date	July 20, 2001
First Named Inventor	H. Michael SHEPARD
Art Unit	1631 1645
Examiner Name	<i>Smith</i> Not Yet Assigned
Attorney Docket Number	NB 2017.00

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

[illegible]

RECEIVED

AUG 08 2007

TECH CENTER 1800/2900

**Examiner's
Signature**

Date Considered 12/2/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.

OIPE
 OCT 10 2002
 PATENT & TRADEMARK OFFICE

PTO/SB/08A (10-01)
 Approved for use through 10/31/2002. OMB 0651-0031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 09/910,345
 Filing Date July 20, 2001
 First Named Inventor H.Michael SHEPARD
 Art Unit 1631 1645
 Examiner Name Smith Not Yet Assigned
 Attorney Docket Number NB 2017.00

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

RECEIVED
 OCT 10 2002
 TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
CS	1	WO 01/07454	02-01-01	NewBiotics, Inc.		

Examiner's Signature

[Signature]

Date

Considered 12/2/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.